Inspira Technologies Oxy B.H.N. Ltd(IINN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.45 | Insider Own | 3.82% | Shs Outstand | 43.6M | Perf Week | -9.21% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 41.9M | Perf Month | -35.33% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.03 | Inst Own | 14.69% | Short Float | 2.16% | Perf Quarter | -34.48% |
| Income | -0.01B | P/S | 57.01 | EPS this Y | 122.22% | Inst Trans | 15.32% | Short Ratio | 3.04 | Perf Half Y | -59.67% |
| Sales | 0.00B | P/B | 5.87 | EPS next 5Y | - | ROA | -197.15% | Short Interest | 0.91M | Perf YTD | -57.83% |
| Book/sh | 0.06 | P/C | 5.07 | EPS past 3/5Y | 31.48% 14.99% | ROE | -397.89% | 52W High | -77% ($1.65) | Perf Year | -25.49% |
| Cash/sh | 0.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | -525.23% | 52W Low | 13.18% ($0.34) | Perf 3Y | -73.46% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 25.24% | Gross Margin | -154.67% | Volatility(W/M) | 7.82% 11.03% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 51.15 | Sales Y/Y TTM | - | Oper. Margin | -4710.73% | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.3 | EPS Q/Q | 95.19% | Profit Margin | -4574.39% | RSI (14) | 34.98 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.56 | Sales Q/Q | - | SMA20 | -16.21% ($0.45) | Beta | 2.13 | Target Price | $5 |
| Payout | - | Debt/Eq | 0.67 | Earnings | 2026/3/26 | SMA50 | -21.72% ($0.49) | Rel Volume | 3.9 | Prev Close | $0.37 |
| Employees | 40 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | -5% -100% | SMA200 | -56.43% ($0.87) | Avg Volume(3M) | 0.30M | Price | $0.38 |
| IPO | 2021/7/14 | Option/Short | No/Yes | Trades | 1196 | Volume | 1,163,508 | Change | 1.93% |
🫁 This Israel-based medical device company develops and supplies the FDA-approved blood oxygenation and respiratory support system 'INSPIRA ART100', designed to address the limitations of conventional ventilators and ECMO, along with a real-time blood monitoring solution.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded more than usual. That is 390% of its average volume.
IINN has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +122.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $5,701. Peers typically go for $139.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -73.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 14.7%.
Tap to view numbers
It ranks #108 of 141 in the industry
Based on market cap of $17M.
PMI#106 Picard Medical Inc $18M PER - 
CVRX#107 CVRx Inc $17M PER - IINN#108 Inspira Technologies Oxy B.H.N. Ltd $17M PER - 
SNWV#108 Sanuwave Health Inc $16M PER - 
CTSO#109 Cytosorbents Corp $15M PER - 
FAQ
What kind of company is IINN?
IINN belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of IINN?
The market cap of IINN is approximately $17M, ranking 5,329 within its sector.
What is the 52-week high and low for IINN?
IINN has recorded a 52-week high of $1.65 and a low of $0.34.
